Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Teclistamab pre-approval access in relapsed or refractory multiple myeloma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teclistamab

Teclistamab will be administered subcutaneously (SC).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JNJ-64007957

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Must have relapsed/refractory multiple myeloma (RRMM) and have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care (example. proteasome inhibitors \[PIs\], immunomodulatory imide drugs \[IMIDs\], anti CD38 monoclonal antibodies \[mAbs\] and therapies targeting Exportin 1 \[XPO1\] and B cell maturation antigen \[BCMA\]). Must not be eligible for a clinical trial with teclistamab or other medicines in this setting

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

64007957PTL4001

Identifier Type: OTHER

Identifier Source: secondary_id

CR108846

Identifier Type: -

Identifier Source: org_study_id